Stock Groups

U.S. to buy 1.4 million more courses of Merck’s COVID-19 pill -Breaking

[ad_1]

© Reuters. FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co I

(Reuters) -Merck & Co Inc and partner Ridgeback Biotherapeutics said on Tuesday the U.S. government would buy an additional 1.4 million courses of their COVID-19 pill, molnupiravir.

In June, the U.S. Government agreed to invest $1.2 billion in 1.7 Million Courses.

According to the companies, the government has options for buying additional doses. The contract is valued at $2.2 billion, or 3.1 million courses.

They also mentioned that the U.S. government has additional options for purchasing more than 2,000,000 courses as part of this contract.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]